The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 698K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

42 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
SB-656104-A: a novel 5-HT(7) receptor antagonist with improved in vivo properties.EBI
Glaxosmithkline
Bicyclic piperazinylbenzenesulphonamides are potent and selective 5-HT6 receptor antagonists.EBI
Glaxosmithkline
Discovery of dual positive allosteric modulators (PAMs) of the metabotropic glutamate 2 receptor and CysLT1 antagonists for treating migraine headache.EBI
Eli Lilly
Discovery of selective N-[3-(1-methyl-piperidine-4-carbonyl)-phenyl]-benzamide-based 5-HT1 F receptor agonists: Evolution from bicyclic to monocyclic cores.EBI
Eli Lilly
Discovery of potent, orally bioavailable, selective 5-HT1A/B/D receptor antagonists.EBI
Glaxosmithkline
The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo.EBI
Smithkline Beecham Pharmaceuticals
Phenyl benzenesulfonamides are novel and selective 5-HT6 antagonists: identification of N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide (SB-357134).EBI
Smithkline Beecham Pharmaceuticals
Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists.EBI
Wyeth Research
N-[3-(2-Dimethylaminoethyl)-2-methyl-1H- indol-5-yl]-4-fluorobenzamide: a potent, selective, and orally active 5-HT(1F) receptor agonist potentially useful for migraine therapy.EBI
Eli Lilly
Urotensin-II receptor antagonists: synthesis and SAR of N-cyclic azaalkyl benzamides.EBI
Glaxosmithkline
Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide.EBI
Theravance
Positron Emission Tomography (PET) Imaging Tracers for Serotonin Receptors.EBI
Beijing Normal University
Design, synthesis and evaluation of bicyclic benzamides as novel 5-HT1F receptor agonists.EBI
Eli Lilly
Design, synthesis and biological evaluation of pyridinylmethylenepiperidine derivatives as potent 5-HTEBI
Sunshine Lake Pharma
Substituted furo[3,2-b]pyridines: novel bioisosteres of 5-HT 1F receptor agonists.EBI
Eli Lilly
Novel potent 5-HT(1F) receptor agonists: structure-activity studies of a series of substituted N-[3-(1-methyl-4-piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]amides.EBI
Eli Lilly
Identification of a novel series of selective 5-HT7 receptor antagonists.EBI
Glaxosmithkline
N-Arylsulfonylindole derivatives as serotonin 5-HT(6) receptor ligands.EBI
Merck Sharp & Dohme Research Laboratories
Conformationally restricted indolopiperidine derivatives as potent CCR2B receptor antagonists.EBI
Glaxosmithkline
3-[3-(Piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists.EBI
Merck Sharp & Dohme Research Laboratories
Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist for the symptomatic treatment of benign prEBI
Abbott Laboratories
Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents.EBI
Merck Sharp and Dohme Research Laboratories
Discovery of the first potent, selective 5-hydroxytryptamine1D receptor antagonist.EBI
Glaxosmithkline
Discovery of a potent and selective 5-ht5A receptor antagonist by high-throughput chemistry.EBI
Glaxosmithkline
Discovery of 4-[3-(trans-3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl]-(4S)-oxazolidin-2-one (4991W93), a 5HT(1B/1D) receptor partial agonist and a potent inhibitor of electrically induced plasma extravasation.EBI
Glaxowellcome
Hydrophilic, Potent, and Selective 7-Substituted 2-Aminoquinolines as Improved Human Neuronal Nitric Oxide Synthase Inhibitors.EBI
Northwestern University
Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitorsBDB
Ctxt
Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereofBDB
Beijing Tide Pharmaceutical
Trifluoromethylpropanamide derivativesBDB
Hoffmann-La Roche
Compounds and compositions for inhibiting the activity of SHP2BDB
Novartis
Piperidine oxadiazole and thiadiazole orexin receptor antagonistsBDB
Merck Sharp & Dohme
Heterocyclic compounds and methods for their useBDB
Novartis
Fucosidase inhibitorsBDB
Horizon Orphan
N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disordersBDB
Ogeda
Compounds and methods for kinase modulation, and indications thereforBDB
Plexxikon
Biarylether amide quinolines as liver X receptor agonists.BDB
Wyeth Research
Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-binding, more isoform-selective inhibitors.BDB
Cnr
Structure-Based Design, Synthesis, and Biological Evaluation of a Series of Novel and Reversible Inhibitors for the Severe Acute Respiratory Syndrome-Coronavirus Papain-Like Protease.BDB
Purdue University
Non-peptidic substrate-mimetic inhibitors of Akt as potential anti-cancer agents.BDB
Yale University
N-aryl-oxazolidin-2-imine muscle selective androgen receptor modulators enhance potency through pharmacophore reorientation.BDB
Bristol-Myers Squibb
Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.BDB
Universita Del Piemonte Orientale
Discovery and structure-activity relationship studies of indole derivatives as liver X receptor (LXR) agonists.BDB
Tanabe Research Laboratories Usa